BioMab partners with Vinmec on NK cell therapy studies

By AI, Created 4:45 AM UTC, May 21, 2026, /AGP/ – BioMab has formed a strategic clinical collaboration with Vinmec International General Hospital in Vietnam to test its NK cell expansion kit in clinical and organoid studies. The deal extends BioMab’s push into Southeast Asia and could help advance next-generation cancer immunotherapies.

Why it matters: - The collaboration gives BioMab a clinical foothold in Vietnam, one of Southeast Asia’s emerging healthcare markets. - The work centers on NK cell therapy, a field with potential to strengthen cancer and other disease treatments. - The partnership could support BioMab’s broader strategy to grow its cell and gene therapy business across Asia and beyond.

What happened: - BioMab announced a strategic clinical collaboration with Vinmec International General Hospital in Vietnam on June 1, 2026. - The collaboration will focus on clinical testing and organoid studies using BioMab’s proprietary Natural Killer Cell Expansion Kit, DSNK. - BioMab said the partnership marks a milestone in its international expansion strategy.

The details: - BioMab and Vinmec plan to advance the clinical development of NK cell–based therapies. - The collaboration will also explore translational applications using organoid models. - BioMab said the effort supports development of next-generation immunotherapies for cancer and other diseases. - BioMab CEO Joshua Ho said the partnership reflects confidence in the company’s technology and supports its long-term goal of becoming a leading CGT products provider in Asia and beyond. - BioMab’s DSNK kit is a chemically defined culture medium for expanding NK cells. - BioMab says 10 mL of peripheral blood can generate more than 1 billion NK cells at more than 95% purity. - BioMab says the kit can deliver about 3,000-fold expansion without feeder cells or NK cell purification before expansion. - BioMab says that approach reduces cost, complexity and production variability. - BioMab’s products are distributed across Asia, America and Europe. - BioMab offers cell culture media, diagnostic kits and CDMO services. - Vinmec, developed by Vingroup in 2012, operates nine hospitals and four clinics in Vietnam. - Vinmec Times City and Vinmec Central Park are the first two hospitals in Vietnam to join the Cleveland Clinic Connected network.

Between the lines: - The collaboration pairs a therapy-development company with a hospital system that has clinical infrastructure and research capabilities. - Using organoid models alongside clinical testing suggests BioMab is trying to connect lab work with patient-facing development. - The deal also gives BioMab a regional credibility boost as it tries to expand in Asia.

What’s next: - BioMab and Vinmec are expected to move ahead with testing and organoid research under the collaboration. - The companies aim to advance NK cell-based therapies and related immunotherapy applications. - BioMab cautioned that future clinical development and commercialization results could vary because of regulatory, market or operational factors. - More information